The therapeutic community is buzzing with anticipation surrounding retatrutide, a innovative dual GIP and GLP-1 target that’s exhibiting significant promise in clinical trials for treating obesity. Unlike some current weight loss solutions, retatrutide appears to deliver a significant substantial